Survodutide vs Mazdutide

Both are dual GLP-1 and glucagon receptor agonists. Survodutide has been studied in obesity and MASH (fatty liver disease); mazdutide, an oxyntomodulin analogue, has completed trials in China.

HPLC tested · JanoshikJanoshik CertificatesNationwide DeliveryResearch Only

🧪

Survodutide

A dual glucagon-receptor / GLP-1-receptor agonist being developed for obesity and metabolic liver disease (MASH).

BEST STUDIED FOR

Incretin & metabolic

Read the cited profile →

🧪

	Survodutide	Mazdutide
The key difference	GLP-1/glucagon dual agonist	GLP-1/glucagon dual agonist (oxyntomodulin-based)
Class	Incretin & metabolic	Incretin & metabolic
Mechanism	Modelled on oxyntomodulin, survodutide activates both the GLP-1 receptor (appetite, insulin) and the glucagon receptor (energy expenditure, hepatic fat metabolism) — the rationale for its liver-disease programme.	Like survodutide, mazdutide combines GLP-1 receptor agonism with glucagon-receptor agonism, the latter studied for energy expenditure and liver fat.
Status	Phase 2 in obesity and MASH (2024); phase 3 obesity results reported in 2026. Not yet approved.	Approved in China (2025) for weight management; phase 3 trials in obesity and type 2 diabetes, including a head-to-head versus dulaglutide.
Reported safety signals	Trials report gastrointestinal events as the main tolerability issue, with dose-escalation studied to manage them.	Trials report gastrointestinal events as most common; phase 1b work explored higher doses for tolerability.
A key study	Describes the discovery and preclinical pharmacology of survodutide as an oxyntomodulin-like dual agonist. (Mol Metab 2022, PMID 36356832)	A phase 3 placebo-controlled trial measured weight change with mazdutide in Chinese adults. (N Engl J Med 2025, PMID 40421736)

They answer the same mechanistic question; survodutide carries the liver data, mazdutide the Chinese obesity trials. Both are discussed here strictly as research compounds; nothing on this page is medical advice or a dosing guide.

REFERENCES (PUBMED)

[Survodutide] BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy — Mol Metab 2022. PMID 36356832
[Survodutide] Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial — Lancet Diabetes Endocrinol 2024. PMID 38330987
[Survodutide] A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis — N Engl J Med 2024. PMID 38847460
[Mazdutide] Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight — N Engl J Med 2025. PMID 40421736
[Mazdutide] Mazdutide: First Approval — Drugs 2025. PMID 41028652
[Mazdutide] Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes — Nature 2026. PMID 41407860

FREQUENTLY ASKED

What is the difference between Survodutide and Mazdutide?

Both are dual GLP-1 and glucagon receptor agonists. Survodutide has been studied in obesity and MASH (fatty liver disease); mazdutide, an oxyntomodulin analogue, has completed trials in China.

What is the regulatory status of Survodutide and Mazdutide?

Survodutide: Phase 2 in obesity and MASH (2024); phase 3 obesity results reported in 2026. Not yet approved. Mazdutide: Approved in China (2025) for weight management; phase 3 trials in obesity and type 2 diabetes, including a head-to-head versus dulaglutide.

What safety signals have been reported?

Survodutide: Trials report gastrointestinal events as the main tolerability issue, with dose-escalation studied to manage them. Mazdutide: Trials report gastrointestinal events as most common; phase 1b work explored higher doses for tolerability.

Which studies is this comparison based on?

For Survodutide: “BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy” (PMID 36356832); “Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial” (PMID 38330987); “A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis” (PMID 38847460). For Mazdutide: “Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight” (PMID 40421736); “Mazdutide: First Approval” (PMID 41028652); “Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes” (PMID 41407860).